• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

高铁血红蛋白血症与 8-氨基喹啉类抗疟药的根治效果。

Methaemoglobinaemia and the radical curative efficacy of 8-aminoquinoline antimalarials.

机构信息

Mahidol Oxford Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.

Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

出版信息

Br J Clin Pharmacol. 2022 Jun;88(6):2657-2664. doi: 10.1111/bcp.15219. Epub 2022 Jan 27.

DOI:10.1111/bcp.15219
PMID:34997616
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7612727/
Abstract

Methaemoglobin results from the oxidation of ferrous to ferric iron in the centre of the haem moiety of haemoglobin. The production of dose-dependent methaemoglobinaemia by 8-aminoquinoline antimalarial drugs appears to be associated with, but is not directly linked to, therapeutic efficacy against latent Plasmodium vivax and Plasmodium ovale malarias (radical cure). Iatrogenic methaemoglobinaemia may be a useful pharmacodynamic measure in 8-aminoquinoline drug and dose optimization.

摘要

高铁血红蛋白是由于血红蛋白血红素部分中心的亚铁离子氧化为三价铁离子而产生的。8-氨基喹啉抗疟药物产生剂量依赖性高铁血红蛋白血症似乎与治疗潜伏性间日疟原虫和卵形疟原虫（根治）的疗效有关，但不是直接相关。医源性高铁血红蛋白血症可能是 8-氨基喹啉药物和剂量优化的有用药效学指标。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0a8/7612727/a0fa0d79ee54/EMS140787-f007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0a8/7612727/3e1e885e9399/EMS140787-f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0a8/7612727/b534a3422258/EMS140787-f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0a8/7612727/fbad4ee22018/EMS140787-f003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0a8/7612727/77f14cd9c7f9/EMS140787-f004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0a8/7612727/dbd7d95ec76d/EMS140787-f005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0a8/7612727/0422a897ba8a/EMS140787-f006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0a8/7612727/a0fa0d79ee54/EMS140787-f007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0a8/7612727/3e1e885e9399/EMS140787-f001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0a8/7612727/b534a3422258/EMS140787-f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0a8/7612727/fbad4ee22018/EMS140787-f003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0a8/7612727/77f14cd9c7f9/EMS140787-f004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0a8/7612727/dbd7d95ec76d/EMS140787-f005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0a8/7612727/0422a897ba8a/EMS140787-f006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0a8/7612727/a0fa0d79ee54/EMS140787-f007.jpg

相似文献

1
Methaemoglobinaemia and the radical curative efficacy of 8-aminoquinoline antimalarials.高铁血红蛋白血症与 8-氨基喹啉类抗疟药的根治效果。
Br J Clin Pharmacol. 2022 Jun;88(6):2657-2664. doi: 10.1111/bcp.15219. Epub 2022 Jan 27.
2
Optimal balance of benefit versus risk for tafenoquine in the treatment of Plasmodium vivax malaria.在治疗间日疟原虫疟疾中，以平衡疗效与风险为目标的磷酸萘酚喹。
Malar J. 2024 May 13;23(1):145. doi: 10.1186/s12936-024-04924-z.
3
Methaemoglobin as a surrogate marker of primaquine antihypnozoite activity in Plasmodium vivax malaria: A systematic review and individual patient data meta-analysis.血质红蛋白作为间日疟原虫抗休眠子活性的替代标志物：系统评价和个体患者数据分析荟萃分析。
PLoS Med. 2024 Sep 27;21(9):e1004411. doi: 10.1371/journal.pmed.1004411. eCollection 2024 Sep.
4
Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria.目前对普萘洛尔和他非诺喹根治间日疟的治疗限制的影响。
PLoS Negl Trop Dis. 2018 Apr 20;12(4):e0006440. doi: 10.1371/journal.pntd.0006440. eCollection 2018 Apr.
5
Single dose tafenoquine for preventing relapse in people with plasmodium vivax malaria-an updated meta-analysis.单次服用他非诺喹预防间日疟原虫疟疾复发的疗效：一项更新的荟萃分析。
Travel Med Infect Dis. 2020 Jul-Aug;36:101576. doi: 10.1016/j.tmaid.2020.101576. Epub 2020 Feb 6.
6
Tafenoquine: First Global Approval.他非喹：全球首次批准。
Drugs. 2018 Sep;78(14):1517-1523. doi: 10.1007/s40265-018-0979-2.
7
Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.单次服用他非诺喹预防间日疟原虫疟疾复发。
N Engl J Med. 2019 Jan 17;380(3):215-228. doi: 10.1056/NEJMoa1710775.
8
Quantifying Plasmodium vivax radical cure efficacy: a modelling study integrating clinical trial data and transmission dynamics.间日疟原虫根治疗效的量化：一项整合临床试验数据与传播动力学的建模研究
Lancet Infect Dis. 2025 Jun;25(6):668-677. doi: 10.1016/S1473-3099(24)00689-3. Epub 2025 Jan 13.
9
Probing the distinct chemosensitivity of Plasmodium vivax liver stage parasites and demonstration of 8-aminoquinoline radical cure activity in vitro.探究间日疟原虫肝脏期寄生虫的独特化学敏感性，并在体外证明 8-氨基喹啉自由基治愈活性。
Sci Rep. 2021 Oct 7;11(1):19905. doi: 10.1038/s41598-021-99152-9.
10
Tafenoquine: A Step toward Malaria Elimination.泰法诺喹：迈向疟疾消除的一步。
Biochemistry. 2020 Mar 3;59(8):911-920. doi: 10.1021/acs.biochem.9b01105. Epub 2020 Feb 24.

引用本文的文献

1
Towards next-generation treatment options to combat Plasmodium falciparum malaria.迈向对抗恶性疟原虫疟疾的下一代治疗方案。
Nat Rev Microbiol. 2025 Mar;23(3):178-191. doi: 10.1038/s41579-024-01099-x. Epub 2024 Oct 4.
2
Methaemoglobin as a surrogate marker of primaquine antihypnozoite activity in Plasmodium vivax malaria: A systematic review and individual patient data meta-analysis.血质红蛋白作为间日疟原虫抗休眠子活性的替代标志物：系统评价和个体患者数据分析荟萃分析。
PLoS Med. 2024 Sep 27;21(9):e1004411. doi: 10.1371/journal.pmed.1004411. eCollection 2024 Sep.
3
Response to comment on 'The clinical pharmacology of tafenoquine in the radical cure of malaria: An individual patient data meta-analysis'.

本文引用的文献

1
Determinants of Primaquine and Carboxyprimaquine Exposures in Children and Adults with Plasmodium vivax Malaria.《间日疟原虫感染的儿童和成人中磷酸萘酚喹和羧酸萘酚喹暴露的决定因素》
Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0130221. doi: 10.1128/AAC.01302-21. Epub 2021 Aug 16.
2
Anti-malarial drug effects on parasite dynamics in vivax malaria.抗疟药物对 vivax 疟疾寄生虫动力学的影响。
Malar J. 2021 Mar 21;20(1):161. doi: 10.1186/s12936-021-03700-7.
3
8-Aminoquinoline Therapy for Latent Malaria.8-氨基喹啉疗法治疗潜伏疟疾。
对“磷酸萘酚喹根治疟疾的临床药理学：一项个体患者数据分析荟萃分析”一文的评论的回复。
Elife. 2024 Feb 7;13:e91283. doi: 10.7554/eLife.91283.
4
Characterizing the Blood-Stage Antimalarial Activity of Tafenoquine in Healthy Volunteers Experimentally Infected With Plasmodium falciparum.描述替法诺喹在健康志愿者中抗疟原虫（恶性疟原虫）血期活性的特征。
Clin Infect Dis. 2023 Jun 8;76(11):1919-1927. doi: 10.1093/cid/ciad075.
5
The clinical pharmacology of tafenoquine in the radical cure of malaria: An individual patient data meta-analysis.磷酸萘酚喹根治疟疾的临床药理学：一项个体患者数据分析荟萃研究。
Elife. 2022 Dec 6;11:e83433. doi: 10.7554/eLife.83433.
Clin Microbiol Rev. 2019 Jul 31;32(4). doi: 10.1128/CMR.00011-19. Print 2019 Sep 18.
4
Antimalarial activity of primaquine operates via a two-step biochemical relay.伯氨喹的抗疟活性通过两步生化接力来实现。
Nat Commun. 2019 Jul 19;10(1):3226. doi: 10.1038/s41467-019-11239-0.
5
Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria.氯喹与双氢青蒿素-哌喹联合标准高剂量伯氨喹，分别治疗 7 天和 14 天，用于治疗间日疟原虫疟疾。
Clin Infect Dis. 2019 Apr 8;68(8):1311-1319. doi: 10.1093/cid/ciy735.
6
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.泰非诺喹与伯氨喹预防间日疟复发。
N Engl J Med. 2019 Jan 17;380(3):229-241. doi: 10.1056/NEJMoa1802537.
7
Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.单次服用他非诺喹预防间日疟原虫疟疾复发。
N Engl J Med. 2019 Jan 17;380(3):215-228. doi: 10.1056/NEJMoa1710775.
8
Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype With Therapeutic Efficacy of Primaquine Treatment for Latent Plasmodium vivax Malaria.细胞色素 P450 2D6 活性基因型和表型受损与磷酸萘酚喹治疗潜伏性间日疟原虫疟疾的疗效相关性研究。
JAMA Netw Open. 2018 Aug 3;1(4):e181449. doi: 10.1001/jamanetworkopen.2018.1449.
9
Contribution of Asymptomatic Plasmodium Infections to the Transmission of Malaria in Kayin State, Myanmar.缅甸克耶邦无症状疟原虫感染对疟疾传播的贡献。
J Infect Dis. 2019 Apr 16;219(9):1499-1509. doi: 10.1093/infdis/jiy686.
10
Enantiospecific pharmacokinetics and drug-drug interactions of primaquine and blood-stage antimalarial drugs.手性药物动力学和疟原虫血期抗疟药物与伯氨喹的药物相互作用。
J Antimicrob Chemother. 2018 Nov 1;73(11):3102-3113. doi: 10.1093/jac/dky297.